TITLE:
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

CONDITION:
Multiple Myeloma

INTERVENTION:
CC-5013

SUMMARY:

      To evaluate the response rate, response duration, and survival of patients treated with
      CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  History of histologically documented multiple myeloma with relapsed or resistant
             disease

          -  Pregnant or nursing women may not participate. Women of childbearing potential must
             have a negative pregnancy documented within one week of registration. Women of
             reproductive potential may not participate unless they have agreed to use an
             effective contraceptive method.

          -  Signed written informed consent and willingness to meet follow-up schedule and study
             procedure obligations
      
